We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+20.21%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.06B
AUM Growth
-$300M
(-13%)
Cap. Flow
-$581M
Cap. Flow
% of AUM
-28.26%
Top 10 Holdings %
Top 10 Hldgs %
86.31%
Holding
41
New
11
Increased
3
Reduced
4
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRAX
First Tracks Biotherapeutics
TRAX
|
+$59.3M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$39.8M |
| 3 |
CG Oncology
CGON
|
+$25.6M |
| 4 |
Legend Biotech
LEGN
|
+$21.6M |
| 5 |
Stoke Therapeutics
STOK
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$323M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$238M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$156M |
| 4 |
Xencor
XNCR
|
+$26.3M |
| 5 |
Relay Therapeutics
RLAY
|
+$17.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.95% |
| 2 | Miscellaneous | 1.95% |
| 3 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Nurix Therapeutics
NRIX
$2.72B
| $6.55M | 0.32% |
+270,000
| New | +$4.6M |
|
27
Erasca
ERAS
$6.31B
| $6.05M | 0.29% |
330,000
-570,000
| -63% | -$8.15M |
|
|
ELOX
28
Eloxx Pharmaceuticals
ELOX
$51.8M
| $5.55M | 0.27% |
+400,000
| New | +$5.1M |
|
|
AARD
29
Aardvark Therapeutics
AARD
$127M
| $2.28M | 0.11% |
+396,194
| New | +$1.85M |
|
|
HLXC
30
Helix Acquisition Corp III
HLXC
$238M
| $2.13M | 0.1% |
200,000
| – | – |
|
|
MREO
31
Mereo BioPharma
MREO
$40.3M
| $318K | 0.02% |
1,000,000
-12,368,855
| -93% | -$3.71M |
|
|
SRZNW
32
DELISTED
Surrozen Inc Warrant
SRZNW
| $115K | 0.01% |
4,444
| – | – |
|
|
AARD
33
CALL
Aardvark Therapeutics
AARD
$127M
| $84.7K | ﹤0.01% |
+14,700
| New | +$68.7K |
|
|
CNTA
34
CALL
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-410,800
| Closed | -$16.3M |
|
|
CNTA
35
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-6,000,000
| Closed | -$238M |
|
|
36
Crinetics Pharmaceuticals
CRNX
$9B
| – | – |
-4,288,120
| Closed | -$156M |
|
37
iBio
IBIO
$67.6M
| – | – |
-1,583,000
| Closed | -$3.01M |
|
|
38
Jazz Pharmaceuticals
JAZZ
$15.9B
| – | – |
-1,706,469
| Closed | -$323M |
|
39
Prelude Therapeutics
PRLD
$437M
| – | – |
-947,049
| Closed | -$3.24M |
|
40
Replimune Group
REPL
$1.46B
| – | – |
-1,000,000
| Closed | -$7.65M |
|
|
41
Xencor
XNCR
$1.94B
| – | – |
-2,183,000
| Closed | -$26.3M |
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q2 2026 Portfolio in Review
As of Q2 2026, EcoR1 Capital held 41 positions worth $2.06B, down 13% from $2.36B the previous quarter. Its ten largest holdings account for 86% of the portfolio.
EcoR1 Capital withdrew a net $581M in Q2 2026, closing 8 positions and reducing 4 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $323M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, EcoR1 Capital opened a new position in First Tracks Biotherapeutics worth $63.9M.
- EcoR1 Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 3,174,519 shares worth $63.9M.
- EcoR1 Capital added most to CG Oncology in Q2 2026, an estimated $25.6M increase.
- EcoR1 Capital's biggest Q2 2026 reduction was Relay Therapeutics, cutting an estimated $17.5M.
- EcoR1 Capital fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $323M.
- EcoR1 Capital's ten largest holdings make up 86% of its $2.06B portfolio in Q2 2026.
- EcoR1 Capital opened 11 new positions and closed 8 in Q2 2026.
- EcoR1 Capital's portfolio value fell 13% quarter-over-quarter to $2.06B.
Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.